ID SOLUTIONS and Oncobit join forces to make cancer diagnosis and monitoring faster and more personalised thanks to digital PCR
Montpellier, France, and Zurich, Switzerland – December 2025
ID Solutions and Oncobit AG announce a strategic partnership to accelerate the development and deployment of innovative tests that rapidly detect cancer biomarkers from a simple blood sample. This collaboration strengthens both companies’ commitment to advancing precision oncology.
The partnership brings together the complementary expertise of two leaders in their respective fields:
- ID Solutions, a French expert in developing digital PCR–based tests, leveraging technology capable of detecting extremely low quantities of tumor DNA, crucial for modern oncology applications.
- Oncobit, a Swiss company recognized for its monitoring assays and analytical software, which enables clinicians to easily interpret results and track disease progression throughout the patient journey.
Together, the two companies will develop a new generation of user-friendly oncology tests designed to support clinicians in making faster and more personalized treatment decisions. All tests developed under this partnership will comply with IVDR (In Vitro Diagnostic Regulation), meeting European regulatory requirements for clinical diagnostic use.
In practice, this partnership will:
- Deliver results in under 24 hours to identify key genetic biomarkers used in targeted cancer therapies, helping physicians rapidly select the most appropriate treatment;
- Enable treatment monitoring by quantifying tumor-derived biomarkers in the blood, allowing for more precise and timely therapeutic adjustments.
The patented technologies of ID Solutions and Oncobit form a solid foundation for delivering highly sensitive and reliable oncology diagnostics that can be used both in major hospitals and decentralized laboratories. This paves the way for cancer care that is faster, more personalized, and more accessible.
“ By partnering with Oncobit, we are taking a major step toward bringing digital PCR into clinical oncology diagnostics and patient monitoring,” said Lise Grewis, President of ID Solutions. “Being able to detect cancer biomarkers in less than 24 hours and follow disease evolution in real time provides clinicians with a new way to support their patients more rapidly and more precisely.”
“This partnership reflects our shared vision of making personalized oncology care accessible worldwide,” added Dr. Claudia Scheckel, CEO of Oncobit AG. “By combining our complementary expertise, we are equipping clinicians with precision tools that set new standards in sensitivity, reliability, and patient monitoring.”
This collaboration represents a significant advancement in the fight against cancer. By combining technological innovation, clinical expertise, and industrial rigor, ID Solutions and Oncobit are laying the foundation for a new generation of oncology diagnostics that deliver accurate, real-time results and truly patient-centric.
About ID Solutions
ID Solutions is a French company based in Montpellier, specialising in the development of innovative diagnostic solutions in oncology. A pioneer in the field of liquid biopsy and digital PCR, ID Solutions develops tools capable of detecting and monitoring cancers from a simple blood sample, with a high degree of reliability. The company is known for its ability to validate and control the entire analytical process. This guarantees fast, accurate and standardised results for clinicians and patients.
For further informations: www.id-solutions.fr/en
About Oncobit
Oncobit is a leading Swiss company in precision oncology. It has developed a scalable cancer-monitoring platform based on the highly sensitive detection of tumor biomarkers in blood samples. Its cloud-based analytical software, trained on data from both patients and healthy individuals, ensures robust and standardized reporting. Oncobit’s solutions are used by an increasing number of clinical laboratories, hospitals, and pharmaceutical partners.
For further informations: https://oncobit.com/en/